We are live on
!
Find out more
RA
Royce & Associates Portfolio holdings
AUM
$12.4B
1-Year Est. Return
64.17%
This Fund
S&P 500
This Quarter
Est. Return
+28.76%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$12.4B
AUM Growth
+$2.29B
(+23%)
Cap. Flow
-$8.07M
Cap. Flow
% of AUM
-0.07%
Top 10 Holdings %
Top 10 Hldgs %
9.07%
Holding
848
New
74
Increased
361
Reduced
233
Closed
101
Avg Time Held
18.2
quarters
Top 10 Avg Time Held
3.2
quarters
Top 20 Avg Time Held
7.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Manhattan Associates
MANH
|
+$43.3M |
| 2 |
Mine Safety
MSA
|
+$37.1M |
| 3 |
Yesway Inc
YSWY
|
+$34.7M |
| 4 |
Dorman Products
DORM
|
+$24.6M |
| 5 |
Avantor
AVTR
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cohu
COHU
|
+$54.5M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$51.1M |
| 3 |
MKS Inc
MKSI
|
+$44.5M |
| 4 |
Vishay Intertechnology
VSH
|
+$40.2M |
| 5 |
Littelfuse
LFUS
|
+$35.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 26.88% |
| 2 | Technology | 19.45% |
| 3 | Financials | 14.84% |
| 4 | Consumer Discretionary | 12.86% |
| 5 | Healthcare | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
326
Stride
LRN
$3.51B
| $12.7M | 0.1% |
147,255
+27,508
| +23% | +$2.53M |
2022 Q4
14 quarters
|
|
327
Zevra Therapeutics
ZVRA
$672M
| $12.7M | 0.1% |
882,658
-106,016
| -11% | -$1.18M |
2025 Q3
3 quarters
|
|
328
Axcelis
ACLS
$3.94B
| $12.4M | 0.1% |
65,700
-59,580
| -48% | -$8.84M |
2018 Q4
30 quarters
|
|
329
Apogee Enterprises
APOG
$855M
| $12.4M | 0.1% |
272,000
+38,939
| +17% | +$1.45M |
2024 Q1
9 quarters
|
|
330
OceanFirst Financial
OCFC
$1.56B
| $12.2M | 0.1% |
622,226
+137,696
| +28% | +$2.57M |
2024 Q2
8 quarters
|
|
331
Flowco Holdings
FLOC
$847M
| $12.1M | 0.1% |
567,850
+112,350
| +25% | +$2.68M |
2025 Q2
4 quarters
|
|
332
Spire Global
SPIR
$378M
| $12.1M | 0.1% |
650,430
+80,430
| +14% | +$1.5M |
2026 Q1
1 quarter
|
|
333
Collegium Pharmaceutical
COLL
$718M
| $12M | 0.1% |
332,065
+59,279
| +22% | +$2.03M |
2023 Q3
11 quarters
|
|
334
Ribbon Communications
RBBN
$281M
| $11.9M | 0.1% |
5,090,927
+211,186
| +4% | +$557K |
2023 Q1
13 quarters
|
|
335
Minerals Technologies
MTX
$1.96B
| $11.9M | 0.1% |
160,947
+682
| +0.4% | +$51.5K |
2013 Q2
52 quarters
|
|
336
American Outdoor Brands
AOUT
$207M
| $11.9M | 0.1% |
1,010,254
+94,224
| +10% | +$916K |
2022 Q3
15 quarters
|
|
337
UFP Technologies
UFPT
$2.29B
| $11.8M | 0.09% |
44,465
+20,598
| +86% | +$4.47M |
2026 Q1
1 quarter
|
|
338
CeriBell Inc
CBLL
$969M
| $11.8M | 0.09% |
605,010
+89,290
| +17% | +$1.69M |
2025 Q4
2 quarters
|
|
339
Timberland Bancorp
TSBK
$352M
| $11.7M | 0.09% |
260,826
-2,108
| -0.8% | -$87.2K |
2013 Q2
52 quarters
|
|
340
Teledyne Technologies
TDY
$28.4B
| $11.6M | 0.09% |
17,440
| – | – |
2022 Q1
17 quarters
|
|
341
Kingstone Companies
KINS
$272M
| $11.6M | 0.09% |
611,067
+75,410
| +14% | +$1.22M |
2025 Q4
2 quarters
|
|
342
Corcept Therapeutics
CORT
$13.1B
| $11.6M | 0.09% |
133,300
-2,130
| -2% | -$129K |
2018 Q2
32 quarters
|
|
343
Almonty Industries
ALM
$3.2B
| $11.6M | 0.09% |
698,170
+32,670
| +5% | +$623K |
2025 Q4
2 quarters
|
|
344
State Street SPDR Portfolio S&P 600 Small Cap ETF
SPSM
$15.9B
| $11.6M | 0.09% |
200,373
-7,350
| -4% | -$392K |
2025 Q4
2 quarters
|
|
345
Commault Systems
CVLT
$6.44B
| $11.5M | 0.09% |
+81,000
| New | +$8.7M |
2026 Q2
0 quarters
|
|
346
Astec Industries
ASTE
$909M
| $11.4M | 0.09% |
187,086
+172,341
| +1,169% | +$9.51M |
2025 Q3
3 quarters
|
|
347
SiteOne Landscape Supply
SITE
$3.84B
| $11.3M | 0.09% |
99,100
+23,010
| +30% | +$2.78M |
2025 Q2
4 quarters
|
|
348
IBEX
IBEX
$594M
| $11.3M | 0.09% |
372,579
+7,925
| +2% | +$236K |
2020 Q3
23 quarters
|
|
349
Mesa Laboratories
MLAB
$717M
| $11.3M | 0.09% |
113,395
-47,834
| -30% | -$4.81M |
2013 Q2
52 quarters
|
|
350
Maravai LifeSciences
MRVI
$1.05B
| $11.3M | 0.09% |
1,808,448
| – | – |
2024 Q1
9 quarters
|
|
Similar funds
JF
WRCM
LC
AIM
SC
ERSOT
BAMF
Royce & Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Royce & Associates held 848 positions worth $12.4B, up 23% from $10.1B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Royce & Associates's Q2 2026 filing shows 74 new, 361 increased, 233 reduced and 101 closed positions. Its largest new stake was Manhattan Associates: 314,304 shares worth $43.8M. The largest sale was Cohu, an estimated $54.5M.
By sector, the portfolio is most concentrated in Industrials at 27% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
- Royce & Associates's largest Q2 2026 buy was Manhattan Associates: 314,304 shares worth $43.8M.
- Royce & Associates added most to Mine Safety in Q2 2026, an estimated $37.1M increase.
- Royce & Associates's biggest Q2 2026 reduction was Cohu, cutting an estimated $54.5M.
- Royce & Associates fully exited Transmedics in Q2 2026, selling an estimated $24.3M.
- Royce & Associates's ten largest holdings make up 9.1% of its $12.4B portfolio in Q2 2026.
- Royce & Associates opened 74 new positions and closed 101 in Q2 2026.
- Royce & Associates's portfolio value rose 23% quarter-over-quarter to $12.4B.
Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.